Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
Consolidated Financial Results for Q3 FY2025 YTD (IFRS)
Q3 FY2025 Financial Results Corporate Presentation
Notice of Completion of Subject Enrollment in the Phase 3 Clinical Trial of Pirfenidone Capsule for the Treatment of Pneumoconiosis
Notice of Phase 3 Trial Results of F351 (Hydronidone) at AASLD-The Liver Meeting 2025
Notice of Completion of Subject Enrollment in the Phase 1 Clinical Trial of Novel Non-Opioid Pain Product Candidate CG001419 Developed by Key Subsidia
[Delayed]Questions from Investors and Answers
Notice Regarding Appointment of Executive Officer
[Delayed] Q2 FY2025 Financial Results Corporate Presentation
Consolidated Financial Results for Q2 FY2025 YTD (IFRS)
Notice Regarding Adjustment of Exercise Price, etc.
Notice Regarding Acquisition of Additional Shares of Gyre Pharmaceuticals by Gyre Therapeutics and Increase in the Group’s Equity Interests
Announcement Regarding Determination of Issue Price and Other Matters
Announcement Regarding Issuance of New Shares by way of International Offering
Results of Special Meeting of Pulmatrix, Inc., Cullgen's Reverse Merger Counterparty
Announcement of First Dosing in Phase 1 Clinical Trial of F230 for Pulmonary Arterial Hypertension (PAH) by Gyre Therapeutics
Announcement of the Launch of Etorel (Nintedanib Esilate Soft Capsules) by Gyre Pharmaceuticals
Notice Regarding Completion of Payment for Public Offering of New Shares by Gyre Therapeutics
Announcement Regarding Public Offering of New Shares by Gyre Therapeutics
To Patients Battling Hepatitis B, and to Our Supportive Shareholders
Regarding the Results of the Phase 3 Clinical Trial of Liver Fibrosis Treatment Drug F351 in China